Research Article Clinical Evaluation of a Novel Tablet Formulation of Traditional Thai Polyherbal Medicine Named Nawametho in Comparison with Its Decoction in the Treatment of Hyperlipidemia Patcharawalai Jaisamut , 1,2 Channong Tohlang , 1,2 Subhaphorn Wanna , 1,2 Acharaporn Thanakun , 3 Thawatchai Srisuwan , 1,2 Surasak Limsuwan , 1,2 Wissava Rattanachai , 4 Jarinee Suwannachot , 4 and Sasitorn Chusri 5 1 Faculty of Traditional ai Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, ailand 2 Traditional ai Medical Research and Innovation Center, Faculty of Traditional ai Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, ailand 3 Department of ai Traditional Medicine, Ban Ta Khun Hospital, Ban Ta Khun, Surat ani 84230, ailand 4 Department of ai Traditional Medicine, Singhanakhon Hospital, Singhanakhon, Songkhla 90280, ailand 5 School of Health Science, Mae Fah Luang University, Muang, Chiang Rai 57100, ailand Correspondence should be addressed to Sasitorn Chusri; sasitorn.chu@mfu.ac.th Received 6 March 2022; Accepted 2 June 2022; Published 3 August 2022 Academic Editor: Mohammed Bourhia Copyright © 2022 Patcharawalai Jaisamut et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the traditional medical system in ailand, medicinal plants and polyherbal medicines have been prescribed as lipid-lowering agents, including Nawametho decoction. is polyherbal formulation is described in the Worayokasan scripture. It consists of nine medicinal plants (Aegle marmelos (L.), Carthamus tinctorius L., Hibiscus sabdariffa Linn., Phyllanthus emblica L., Piper longum L., Piper nigrum L., Terminalia bellirica (Gaertn.) Roxb., Terminalia chebula Retz., and Zingiber officinale Roscoe). Apart from its utilization in ai traditional medicine, there is a lack of evidence supporting its use. is research work thereby aims to formulate and evaluate the tablet containing Nawametho decoction. e feasibility of Nawametho decoction and NawaTab for patients with borderline hyperlipidemia was additionally examined using a prospective, open-label, randomized, parallel-group design. e dry granulation technique was employed to formulate the polyherbal tablets. e tablets were developed using the spray-dried Nawametho decoction as the active ingredient in addition to other excipients. e chosen formulation, the F B (NawaTab), consisted of 385 milligrams of the extract, 12% w/w of a diluent (lactose), 8% w/w of a lubricant (magnesium stearate), 5% w/w of a disintegrant (microcrystalline cellulose), and 5% w/w of an anti-adherent (talcum). eir hardness, friability, and disintegration time were 4.4 ± 0.32 kg, 0.05 ± 0.02%, and 4.60 ± 0.05 min, respectively. Accelerated stability study results revealed that NawaTab was stable for six months at 40 ° C/75% RH and 25 ° C/60% RH. Even though taking NawaTabs (500 mg twice daily) for eight consecutive weeks was unable to improve the lipid profile of the patients, the administration of Nawametho decoction (30 mL twice daily) was associated with a significant decrease in serum triglycerides of the patients. e results show that the dry granulation technique is suitable for the formulation of NawaTab based on the tablet evaluation. Furthermore, the triglyceride- lowering effect of Nawametho decoction was reported for the first time. Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2022, Article ID 2530266, 10 pages https://doi.org/10.1155/2022/2530266